Manhattan Research Releases Report on the Future of Physician Customer Service Portals

Manhattan ResearchOver the past year, physician visitation to customer service portals decreased while interest in using them actually increased. To help biopharma companies bridge the gap between the current portal landscape and unmet physician demand, pharmaceutical and healthcare market research company Manhattan Research just released its latest physician module report, "The Case for Customer Care: Service Portals and a Successfully Integrated CRM System" as part of its ePharma Physicianâ v8.0 market research and strategic advisory service. The report discusses future implications for physician customer service portals and reveals market data and best practices for biopharma companies looking to reach target audiences through this channel.

"Physicians rely on a diverse channel mix to gather biopharma and healthcare information and fewer of them are willing to take face-to-face sales rep meetings - challenging companies to re-invent the traditional service model," said the author of the report, Meredith Abreu Ressi, VP of research for Manhattan Research. "Many have begun building full-service portals for physicians where they can access journal reprints, order samples, download patient education information, and even videoconference online with a rep."

"Physicians are not saying that they want to do away with the sales force entirely," continues Ressi. "Most physicians still want to be able to talk to a rep when they have a question, or when there's a new product launch - but if it's a routine question or transaction, they'd prefer to conduct those activities online, when it's convenient for them. This is really about providing physicians with a variety of channels to access information so they can choose the method that is most convenient and useful to them."

Report Outline
I. Physician Portals: Where Are We Now?

  • Trending and Current Adoption
  • Top Portals
  • Physician Demand for Portals (by company)
  • Who Uses Portals Today?

II. Developing a Physician Portal: Features and Physician Expectations

  • What Are They Using? What do They Want to Use?
  • Differences by Specialty
  • Features to Consider
    • Email Customer Service
    • Live Video Rep or Call Center
    • Integrating Medical Affairs

III. If You Build It, They Won’t Just Come: Marketing Your Portal

  • Marketing the Portal Online
  • Top Portals
  • Selling the Site: Public vs. Password-Protected Content
  • Sales Force Buy-in
  • Closed Loop CRM

More information about the report’s contents can be found here:
http://www.manhattanresearch.com/products/Research_Modules/
Physician/physician-customer-service-portals.aspx

About ePharma Physician® v8.0
ePharma Physician® v8.0 was conducted via online survey methodology in Q2 2008 among 1,681 online practicing U.S. physicians. The study and advisory service product has determined the leading online physician destinations based on the number of physician visitors as well as the content satisfaction of those who visit and provides in-depth analysis of top product and corporate pharmaceutical websites, health portals, online journal sites, specialty-specific sites, newsletters, society sites, physicians and Web 2.0, physician online communities, electronic detailing, Tablet PCs, online conferences, physician customer service portals, tech-enabled sales forces, physician CRM, and more. For more information, visit: http://www.manhattanresearch.com/products/Strategic_Advisory/ePP/

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory firm for pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

Most Popular Now

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

Novartis and Molecular Partners report positive to…

Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

Bayer and Mammoth Biosciences to collaborate on no…

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboratio...

Amgen and Arrakis Therapeutics announce multi-targ…

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a rang...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

New Vaxzevria data further support its use as thir…

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a ...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...